Literature DB >> 7482816

Risk factors and pathogenesis of posttransplant lymphoproliferative disorders.

M Ho1.   

Abstract

Entities:  

Mesh:

Year:  1995        PMID: 7482816

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

Review 1.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 2.  Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.

Authors:  Olivia Hatton; Olivia M Martinez; Carlos O Esquivel
Journal:  Pediatr Transplant       Date:  2012-02-21

3.  Double-step PCR assay to quantify Epstein-Barr viral load in peripheral blood.

Authors:  Massimiliano Bergallo; Chiara Merlino; Roberta Daniele; Franca Sinesi; Mara Fumagalli; Alessandro Negro Ponzi; Rossana Cavallo
Journal:  Mol Biotechnol       Date:  2004-07       Impact factor: 2.695

4.  Severe obstructive sleep apnoea due to adenotonsillar hypertrophy after liver transplantation.

Authors:  Omar Mulla; Yogesh Bajaj; Lindsey Knight
Journal:  BMJ Case Rep       Date:  2012-12-04

Review 5.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  The post-transplant lymphoproliferative disorder-a literature review.

Authors:  Rokshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714

7.  Oral carcinoma development after 23 years of renal transplantation.

Authors:  Isabel Schausltz Pereira Faustino; Diego Teztner Fernandes; Alan Santos-Silva; Pablo Agustin Vargas; Marcio Ajudarte Lopes
Journal:  Autops Case Rep       Date:  2019-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.